The leader in microbial genomics was granted a patent for a new method and system of microbiome analysis.
San Francisco, CA (PRWEB) - uBiome, the leader in microbial genomics, announces the issue of patent number 9,663,831 entitled “Method and System for Microbiome Analysis” by the US Patent and Trademark Office on May 30, 2017 with a priority date of January 25, 2014. The patent is an invention by uBiome co-founders Dr. Zachary Apte and Dr. Jessica Richman.
The patented technology involves a method and system for analyzing the microbiome of an individual by providing a sampling kit with a lysing component and a sample preservation component to an individual at a remote location. That individual then provides a biological sample and ships the container with their sample to the laboratory. Upon receiving that sample container, a microbiome sequence dataset is generated, microorganisms are identified, and analysis based on a set of features is generated and provided to the individual.
As the microbiome is suspected to play at least a partial role in a number of health- and disease-related states, this issuance will lead to further development in characterization of the human microbiome and generation of insights at the individual- and population-wide levels.
“Securing intellectual property supports uBiome in achieving our mission,” Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are excited to have been granted this first patent, which creates a new, useful method for performing microbiome analysis.”
For more information about our science and intellectual property, visit http://www.ubiome.com/science/#patents.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.